2nd Annual Brilliant Collisions | AI BioHub Showcase

This showcase features the second cohort of LabCentral’s AI BioHub Accelerator, developed in partnership with C10 Labs. These early-stage companies are applying AI to advance human health in ways that are already beginning to take shape across the industry.

Join us to hear directly from the teams behind the work; what they’re building, where they’re pushing boundaries, and what comes next.

We’ll also host a panel conversation exploring the future of early investments in AI and Biotech.

Supported by the Commonwealth of Massachusetts, the AI BioHub reflects a broader commitment to advancing innovation across the life sciences.

Adelle Diagnostics: Adelle Diagnostics is building an AI-powered molecular diagnostics platform to transform dementia care by enabling precise predictions of treatment response, starting with NPH.

Alces Bioworks: Alces Bioworks uses generative AI and lab automation to rapidly design and make superior affinity reagents they call Alceins™.

AracodeX: AracodeX is building an AI-enabled programmable molecular infrastructure to control how drugs are delivered and activated in the body for next-generation drug conjugates and targeted therapeutics. 

Causal AI: Causal Data AI generates experimental ground truth data proving whether drugs work in human tissue. Using patient organoids, active perturbation, and causal AI models, the platform validates drug mechanisms before clinical trials—de-risking pharma's billion-dollar development decisions.

Collixion Therapeutics: Collixion Therapeutics is developing therapies that prevent cancer relapse by targeting how tumors adapt to treatment, starting with ovarian cancer.

Find.Bio: Find.Bio is reverse engineering biology, using AI and large-scale molecular simulations to discover drugs, targets, and predict toxicity.

HarborSite: HarborSite uses large gene insertions by AI-designed recombinases to treat human diseases and enhance biological systems.

Harmonia Therapeutics: Harmonia Therapeutics engineers logic-gated ADCs that sense and respond to their extracellular and intracellular environment to activate exclusively in cancer cells, dramatically improving safety and efficacy for treatment-resistant cancers.

HeraHealth: HeraHealth is an AI-driven SaMD that accurately quantifies postpartum blood loss in real time to provide data-driven support so clinicians can identify hemorrhage sooner and expedite treatment.

Hiba Therapeutics: Hiba Therapeutics is an AI-enabled programmable immunotherapy platform that harnesses the power bystander T cells to specifically target and attack cancer cells with exquisite safety and efficacy.

Intertwined: Intertwined Biosciences is harnessing the results of evolution with AI-native discovery to design regenerative therapeutics.

Meteor Biosciences: Meteor Biosciences is developing a new class of bioenergetic medicines designed through its metabolic intelligence platform to reverse complex disease by restoring healthy metabolic function in diseased cells.

ScriptBio AI: ScriptBio AI is an AI-driven platform discovering causal gene targets in aging-related disease and engineering stem cells to correct them.

Seedbox Labs: Seedbox Labs is building the first reusable, AI-powered, clinical-grade at-home platform for WHO-standard semen analysis and longitudinal male fertility tracking.

Tiller Therapeutics: Tiller Therapeutics utilizes proprietary ML-driven in silico discovery and lead opt platform to identify and optimize targeted small molecule therapies with a tunable wide therapeutic index to treat solid tumors.

Registration for this event is now closed. If you have a question about your registration, please email Ashley Auger (aauger@labcentral.org).